Immunine

Human Coagulation Factor IX, the active ingredient in Immunine, is a coagulation factor presented as a sterile intravenous solution for intravenous use. It treats hemophilia B and other factor IX deficiencies in patients who require replacement therapy.

GNH USA supplies Immunine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Immunine is a hemostatic agent that replaces deficient factor IX in the intrinsic coagulation pathway.

Hemophilia B: restores clotting ability and reduces bleeding episodes. Acquired factor IX deficiency: provides necessary factor IX to re‑establish normal coagulation. Prevention and control of bleeding in patients with factor IX deficiency: helps maintain hemostasis during surgery or trauma.

Immunine may be associated with infusion‑related and systemic reactions.

Common Side Effects: - Infusion‑related reactions such as flushing or chills. - Fever. - Headache. - Nausea.

Serious or Rare Side Effects: - Anaphylactic reactions. - Development of neutralizing antibodies (inhibitors) against factor IX. - Thrombotic events. - Disseminated intravascular coagulation (DIC).

Use of Immunine requires careful clinical monitoring and adherence to safety guidelines.

Dosing individualized: dosage is calculated based on patient’s factor IX activity and clinical need. Monitor for inhibitor development: regular testing for antibodies against factor IX is recommended. Assess hypersensitivity: evaluate for prior allergic reactions to plasma‑derived products before infusion. Use cautiously in cardiovascular disease: patients with a history of thrombosis should be closely observed. Avoid in patients with known severe allergy to factor IX products: contraindicated if hypersensitivity is documented. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunine can interact with other agents that affect coagulation or immune response.

Major Interactions (Avoid): - Concurrent use of other clotting factor concentrates – may increase risk of inhibitor formation. - Use with procoagulant agents (e.g., activated prothrombin complex concentrates) – heightened thrombosis risk.

Moderate Interactions (Monitor Closely): - Antifibrinolytic agents such as tranexamic acid – may augment clot stability and increase thrombosis potential. - Immunosuppressive drugs – could reduce the efficacy of factor IX replacement. - Certain antibiotics affecting liver function – may alter plasma protein handling, requiring monitoring.